Belite Bio, Inc (BLTE): R&D Expense
$45.38M
Year ended 2025-12-31
+72.3%
3-year compound annual growth
+65.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $45.38M | +51.6% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $29.94M | +20.5% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $24.84M | +180.1% | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | $8.87M | +19.5% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $7.42M | +101.2% | 2024-03-12, From 2021-01-01 |
| 2020-12-31 | $3.69M | n/a | 2023-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Belite Bio, Inc (BLTE) | 2025-12-31 | $45.38M | +51.6% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $171.65M | +5.4% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $17.40M | -9.5% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| MannKind Corp (MNKD) | 2025-12-31 | $66.35M | +44.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $170.64M | +76.5% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $197.10M | +54.4% |
Compare BLTE, SYRE, MRVI, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗